Issue Date: November 3, 2008
Glaxo To Buy Genelabs Technologies
GlaxoSmithKline has reached a definitive agreement to buy Genelabs Technologies for $57 million. Genelabs is a Redwood City, Calif.-based drug discovery firm now focusing on novel compounds that selectively inhibit replication of the hepatitis C virus. The two firms already have a partnership to develop a vaccine against hepatitis E.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society